Sangamo Therapeutics Inc.Find Ratings Reports
SANGAMO THERAPEUTICS INC's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line.
At the same time, stockholders' equity ("net worth") has greatly increased by 37.96% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||13.08||8.92|
|Net Income ($mil)||-13.09||-9.62|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||0.0||142.54|
|Total Assets ($mil)||286.74||157.89|
|Total Debt ($mil)||0.0||3.95|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||-105.27||-107.35|
|Return on Assets||-19.03||-45.38|
|Return on Equity||-29.04||-52.61|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||84.11||70.87|
|Div / share||0.0||0.0|
|Book value / share||2.23||1.92|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1908232.0||1574016.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 10.85 indicates a significant premium versus the S&P 500 average of 3.28 and a significant discount versus the industry average of 20.65. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, SANGAMO THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|SGMO NM||Peers 47.18||SGMO NA||Peers 25.10|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
SGMO's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|SGMO NM||Peers 25.68||SGMO NA||Peers 0.38|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
SGMO's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|SGMO 10.85||Peers 20.65||SGMO 31.38||Peers -0.73|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
SGMO is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
SGMO is expected to have an earnings growth rate that significantly exceeds its peers.
|SGMO 55.77||Peers 78.78||SGMO 88.59||Peers 472.09|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
SGMO is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
SGMO significantly trails its peers on the basis of sales growth